- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02184234
Tolerability of Antistax® in Patients Suffering From Chronic Venous Insufficiency (CVI)
July 11, 2014 updated by: Boehringer Ingelheim
A 6-week, Open, Multicentre Safety Trial to Evaluate the Tolerability Profile of Antistax® Film Coated Tablets (Extr. Vitis Viniferae Siccum), 360 mg/Day Per os, in Male and Female Patients Suffering From Chronic Venous Insufficiency
Main objective: Safety and tolerability of Antistax® film coated tablets
Secondary objective: Effect of Antistax® film coated tablets on subjective symptoms of chronic venous insufficiency
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
65
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
25 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Chronic venous insufficiency stage I or II according to Widmer, e.g., resulting in lower-leg oedema
- Male or female out-patients of any ethnic origin
- Age ranging from 25 to 75 years
Exclusion Criteria:
- Known hypersensitivity to any ingredients of the study medication
- Oedema(s) of non-venous origin, e.g., due to cardiac insufficiency, lymphoedema or decompensated cardiac insufficiency, orthopaedic disturbances
- Florid venous ulcers
- Arterial occlusive disease, irrespective of the severity
- Phlebitis or thrombophlebitis
- Clinical indication for an acute phlebologic intervention, e.g., compressive treatment, phlebectomy, etc.
- Evidence of diabetic micro-angiopathy or polyneuropathy in medical history
- Poor general health (based on the investigator's judgement)
- Addiction to alcohol abuse
- Mental illness and inability (or limited ability) to work, or inability (or limited ability) to follow spoken or written explanations concerning the trial
- Women of child-bearing age not using any reliable contraceptive methods
- Pregnant or lactating women
- Patients previously enrolled in the present study or participating in another clinical study, or who had taken part in another study within the previous 90 days
- Patients receiving compression therapy, high-ceiling diuretics (e.g., furosemide), or any other anti-CVI preparations (e.g., vasoprotectives to treat varicosis, such as heparin-containing preparations, sclerosing agents, or bioflavonoids other than the study medication) during the trial. Medications or measures for CVI had to be stopped 14 day prior to intake of study medication.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Antistax film coated tablets
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number and intensity of serious and non-serious Adverse Events
Time Frame: up to 6 weeks
|
up to 6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Global tolerability assessment by the patient and investigator
Time Frame: after 42 days of treatment
|
after 42 days of treatment
|
Vital sign parameters (blood pressure and pulse rate)
Time Frame: at screening and after 6 weeks
|
at screening and after 6 weeks
|
Subjective symptoms rated on a 10-cm Visual Analog Scale (VAS)
Time Frame: Baseline and after 6 weeks
|
Baseline and after 6 weeks
|
Global assessment of efficacy by the patient and investigator
Time Frame: after 6 weeks
|
after 6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2001
Primary Completion (ACTUAL)
October 1, 2001
Study Registration Dates
First Submitted
July 2, 2014
First Submitted That Met QC Criteria
July 7, 2014
First Posted (ESTIMATE)
July 9, 2014
Study Record Updates
Last Update Posted (ESTIMATE)
July 14, 2014
Last Update Submitted That Met QC Criteria
July 11, 2014
Last Verified
July 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1138.5
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Venous Insufficiency
-
Value Outcomes Ltd.Alfasigma S.p.A.RecruitingChronic Venous Disease | Chronic Insufficiency VenousCzechia
-
State Budgetary Healthcare Institution, National...CompletedEndothelial Dysfunction | Venous Insufficiency of Leg | Venous Insufficiency (Chronic)(Peripheral)Russian Federation
-
GCS Ramsay Santé pour l'Enseignement et la RechercheVivactis M2ResearchRecruitingSuperficial Venous InsufficiencyFrance
-
C. R. BardEnrolling by invitation
-
Medtronic EndovascularCompletedVenous Insufficiency of LegUnited Kingdom, Denmark, Germany, Netherlands
-
Hancock Jaffe Laboratiores, IncSyntactx; AXIOM Real Time MetricsRecruitingDeep Venous Insufficiency (Diagnosis)United States
-
Medtronic EndovascularCompleted
-
TheraclionRecruitingChronic Venous InsufficiencyUnited States, Czechia, Austria
-
Technical University of LisbonFundação para a Ciência e a Tecnologia; Escola Superior de Saúde Dr. Lopes...CompletedChronic Venous InsufficiencyPortugal
-
Angiodynamics, Inc.Completed
Clinical Trials on Antistax film coated tablets
-
Valenta Pharm JSCCompletedInfluenza, Human | Common Cold | Acute Respiratory InfectionRussian Federation
-
Future University in EgyptCompleted
-
Bionorica SECompletedPremenstrual Syndrome | Cyclic MastodyniaCzech Republic
-
H. Lundbeck A/SCompleted
-
Fresenius Medical Care Deutschland GmbHCompletedChronic Kidney Disease | HyperphosphatemiaGermany
-
Valenta Pharm JSCCompletedInfluenza, Human | Common Cold | Acute Respiratory InfectionRussian Federation
-
AbbottRecruitingFunctional DyspepsiaMalaysia, Armenia
-
Boehringer IngelheimCompleted
-
Humanis Saglık Anonim SirketiCompleted